HK Stock Market Move | CANSINOBIO(06185) rose more than 5% as its production base in Malaysia received PIC/S GMP certification.

CANSINOBIO (06185) rose by more than 5%, as of the time of writing, it has increased by 5.53%, with a price of 33.98 Hong Kong dollars, and a turnover of 23.251 million Hong Kong dollars. In terms of news, CANSINOBIO announced last night that the production base of their independently developed ACYW135 Group meningococcal polysaccharide conjugate vaccine (CRM197 carrier) Menhibrix (MCV4) and 13-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxin) Prevenar (PCV13i) has passed the GMP compliance inspection by the Malaysian National Pharmaceutical Regulatory Agency (referred to as "NPRA") PIC/S, and has recently been issued a GMP certificate by the NPRA. The company stated that passing the PIC/S GMP certification signifies that CANSINOBIO's production and quality management system has met the requirements of the international Pharmaceutical Inspection Cooperation Scheme (PIC/S) GMP standards. This achievement will not only help promote the registration and listing of Menhibrix (MCV4) and Prevenar (PCV13i) in Malaysia, but also lay an important foundation for the entry of these two vaccines into other PIC/S member countries and regions, providing key support for the internationalization layout of the company's innovative vaccines.